160 related articles for article (PubMed ID: 31204688)
1. Cruzain structures: apocruzain and cruzain bound to S-methyl thiomethanesulfonate and implications for drug design.
Barbosa da Silva E; Dall E; Briza P; Brandstetter H; Ferreira RS
Acta Crystallogr F Struct Biol Commun; 2019 Jun; 75(Pt 6):419-427. PubMed ID: 31204688
[TBL] [Abstract][Full Text] [Related]
2. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain.
Huang L; Brinen LS; Ellman JA
Bioorg Med Chem; 2003 Jan; 11(1):21-9. PubMed ID: 12467703
[TBL] [Abstract][Full Text] [Related]
3. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi.
Figueiredo da Silva AA; de Carvalho Vieira L; Krieger MA; Goldenberg S; Zanchin NI; Guimarães BG
J Struct Biol; 2007 Feb; 157(2):416-23. PubMed ID: 17011790
[TBL] [Abstract][Full Text] [Related]
6. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
8. Dissecting a novel allosteric mechanism of cruzain: A computer-aided approach.
Hernández Alvarez L; Barreto Gomes DE; Hernández González JE; Pascutti PG
PLoS One; 2019; 14(1):e0211227. PubMed ID: 30682119
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of specificity in the cysteine protease cruzain.
Gillmor SA; Craik CS; Fletterick RJ
Protein Sci; 1997 Aug; 6(8):1603-11. PubMed ID: 9260273
[TBL] [Abstract][Full Text] [Related]
10. Experimental study and computational modelling of cruzain cysteine protease inhibition by dipeptidyl nitriles.
Dos Santos AM; Cianni L; De Vita D; Rosini F; Leitão A; Laughton CA; Lameira J; Montanari CA
Phys Chem Chem Phys; 2018 Sep; 20(37):24317-24328. PubMed ID: 30211406
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel Inhibitors of Cruzain Cysteine Protease of
Prates JLB; Lopes JR; Chin CM; Ferreira EI; Dos Santos JL; Scarim CB
Curr Med Chem; 2024; 31(16):2285-2308. PubMed ID: 37888814
[TBL] [Abstract][Full Text] [Related]
12. The crystal structure of cruzain: a therapeutic target for Chagas' disease.
McGrath ME; Eakin AE; Engel JC; McKerrow JH; Craik CS; Fletterick RJ
J Mol Biol; 1995 Mar; 247(2):251-9. PubMed ID: 7707373
[TBL] [Abstract][Full Text] [Related]
13. Experimental and Computational Study of Aryl-thiosemicarbazones Inhibiting Cruzain Reveals Reversible Inhibition and a Stepwise Mechanism.
Martins LC; de Oliveira RB; Lameira J; Ferreira RS
J Chem Inf Model; 2023 Mar; 63(5):1506-1520. PubMed ID: 36802548
[No Abstract] [Full Text] [Related]
14. Cruzain : the path from target validation to the clinic.
Sajid M; Robertson SA; Brinen LS; McKerrow JH
Adv Exp Med Biol; 2011; 712():100-15. PubMed ID: 21660661
[TBL] [Abstract][Full Text] [Related]
15. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Lima AP; dos Reis FC; Serveau C; Lalmanach G; Juliano L; Ménard R; Vernet T; Thomas DY; Storer AC; Scharfstein J
Mol Biochem Parasitol; 2001 Apr; 114(1):41-52. PubMed ID: 11356512
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach.
de Souza ML; de Oliveira Rezende Junior C; Ferreira RS; Espinoza Chávez RM; Ferreira LLG; Slafer BW; Magalhães LG; Krogh R; Oliva G; Cruz FC; Dias LC; Andricopulo AD
J Chem Inf Model; 2020 Feb; 60(2):1028-1041. PubMed ID: 31765144
[TBL] [Abstract][Full Text] [Related]
17. Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.
Chenna BC; Li L; Mellott DM; Zhai X; Siqueira-Neto JL; Calvet Alvarez C; Bernatchez JA; Desormeaux E; Alvarez Hernandez E; Gomez J; McKerrow JH; Cruz-Reyes J; Meek TD
J Med Chem; 2020 Mar; 63(6):3298-3316. PubMed ID: 32125159
[TBL] [Abstract][Full Text] [Related]
18. Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay.
Wiggers HJ; Rocha JR; Fernandes WB; Sesti-Costa R; Carneiro ZA; Cheleski J; da Silva AB; Juliano L; Cezari MH; Silva JS; McKerrow JH; Montanari CA
PLoS Negl Trop Dis; 2013; 7(8):e2370. PubMed ID: 23991231
[TBL] [Abstract][Full Text] [Related]
19. Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi.
Eakin AE; McGrath ME; McKerrow JH; Fletterick RJ; Craik CS
J Biol Chem; 1993 Mar; 268(9):6115-8. PubMed ID: 8454586
[TBL] [Abstract][Full Text] [Related]
20. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
Engel JC; Doyle PS; Palmer J; Hsieh I; Bainton DF; McKerrow JH
J Cell Sci; 1998 Mar; 111 ( Pt 5)():597-606. PubMed ID: 9454733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
